68 results on '"Nobili V"'
Search Results
2. Role of socio-economic status in observational studies: A study model on non-alcoholic steato-hepatitis (NASH)
3. P018 The Nox2: the new marker of stress oxidative in non-alcoholic steatohepatitis in children
4. P024 The role of hepatic Farnesoid X receptor protein level in hepatic zonal metabolism
5. P170 Ketogenic diet: new applications beyond epilepsy
6. P022 Can we change the outcome of biliary atresia and native liver survival without prophylactic antibiotic therapy after Kasai procedure? A single-center experience
7. P043 Successful use of a mini-invasive approach in pediatric hepatobiliopancreatic surgery and in adult-to-child liver transplantation
8. P023 Isolated intrapulmonary vascular dilatations in children with chronic liver disease without hepatopulmonary syndrome
9. P159 Nutritional rehabilitation via naso-gastric tube in children and adolescents with anorexia nervosa: short- and long-term outcomes
10. P167 Growth failure in Crohn's disease children: may the first treatment have a role?
11. P169 Infantile feeding disorders: when even surgery is not enough. an intriguing clinical case
12. P027 Early referral to transplant centers is a prognostic factor influencing outcomes of pediatric liver transplantation
13. P134 Natural history of artificial nutrition in neuro-disabling children in real life
14. P028 Establishing a SIGENP Italian network for the study of biliary atresia
15. P127 Clinical outcomes of motility disorders: a 30-year retrospective study
16. P074 Infliximab trough level and antibodies in clinical practice in pediatric inflammatory bowel diseases
17. P030 Lipid metabolism in a cohort of children with Wilson disease: an enigmatic issue
18. Impact of proprotein convertase subtilisin/kexin type 7 genetic variation in patients with non-alcoholic fatty liver disease
19. P.09.17 PNPLA3 RS738409 POLYMORPHISM PREDICTS THE DEVELOPMENT AND THE SEVERITY OF HEPATIC STEATOSIS, BUT NOT METABOLIC SYNDROME, IN PATIENTS WITH CELIAC DISEASE
20. Galectin-3+ cells in the liver associate with tissue damage in children with NAFLD
21. Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease
22. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease
23. Reply to: “Fructose, uric acid and zonal differences in NASH”
24. Long-term impact of transmural healing on the clinical outcome of pediatric Crohn's disease
25. FAK depletion/inhibition reduces the expression of liver cancer stem cells markers
26. The correlation of the number of hepatic galectin-3+ cells with NAFLD-related liver damage in children
27. Silencing of the focal adhesion kinase reduces hepatocellular carcinoma growth affecting enhancer of zeste homolog 2 transcription and activity
28. Nocturnal Increase of Circulating Fibroblast Growth Factor 21 is Correlated with Severity of Non-Alcoholic Fatty Liver Disease in Children
29. Validity of Non-Invasive Fibrosis Scores in a Large Cohort of Paediatric NAFLD
30. Efficacy of Mediterranean diet in a peculiar case of non-alcoholic steatohepatitis and hypobetalipoproteinemia
31. P1070 : The marker of macrophage activation soluble CD163 is associated with liver histology in children with non-alcoholic fatty liver disease
32. P0310 : FAK/EZH2 functional interaction is crucial for HCC development and progression both in vivo and in vitro
33. P0988 : Nonalcoholic Fatty Liver Disease: Serum bile acid levels in children and adolescents as marker for progression?
34. P1238 : Intermediate familial intrahepatic cholestasis (IFIC): Phenotypic spectrum within the BRIC-PFIC spectrum
35. LITAF role in in vivo hepatocyte proliferation and in hepatocarcinoma cells
36. NAFLD-nonalcoholic fatty liver disease in overweight/obese child (ow/ob) born SGA (Small for Gestational Age).
37. P280 LPS-INDUCED TRANSCRIPTION FACTORS INVOLVED IN NON-ALCOHOLIC LIVER DISEASE (NAFLD) INFLAMMATORY AND PRO-FIBROGENIC PATTERN
38. Enhancer of Zeste Homolog 2 (EZH2) expression and activation in in vivo and in vitro non-alcoholic fatty liver disease (NAFLD)
39. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD
40. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children
41. Genic correlation between the expression of EZH2 and the degree of liver damage in NAFLD
42. 1397 ATYPICAL JUVENILE HEMOCHROMATOSIS ASSOCIATED WITH HETEROZYGOSITY FOR NOVEL HEMOJUVELIN MUTATIONS
43. 1281 LC3 DEREGULATION AND AUTOPHAGY SUPPRESSION DURING HEPATOSTEATOSIS
44. T-24 Fatty-HepG2 cells release molecules that lead in vitro to activation of hepatic stellate cells and epithelial-to-mesenchymal transition
45. PO74 BENEFICIAL EFFECT OF DIETARY SUPPLEMENTATION WITH GLUCOMANNAN IN CHILDREN WITH NAFLD: PRELIMINARY RESULTS
46. PO72 CHILDREN UNRESPONSIVE TO HEPATITIS B VIRUS VACCINATION NEED CELIAC DISEASE TESTING
47. 1272 DECREASED SERUM LEVELS OF FIBROBLAST GROWTH FACTORS 19 AND 21 CORRELATE WITH SEVERITY OF TISSUE DAMAGE IN PEDIATRIC NAFLD
48. F-10 Emodin partially reverts diet-induced steatosis and completely reverts inflammation and redox status imbalance in rats
49. F-14 Lipopolysaccharide-induced tumor necrosis factor-alpha and hepatic stellate cell proliferation and activation
50. 1258 ROLE OF LIPOPOLYSACCHARIDE-INDUCED TUMOR NECROSIS FACTOR-α IN LIVER DAMAGE DURING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.